Over the past decades, only four PARP inhibitors, namely, olaparib, rucaparib, niraparib, and talazoparib, were originally approved for use as a single agent by the European Medicines Agency (EMA) in the European Union and the FDA in the United States for ovarian cancer (70). This evidence concerns the gene PARP1 and ovarian carcinoma.